Benzinga | Apr 9, 2021 07:04AM EDT

Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity

* Affimed NV (NASDAQ: AFMD) has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell engager (ICE) AFM13 (CD16A/CD30).

* The trial evaluates the pre-complexing of AFM13 with cbNK cells followed by three weekly infusions of AFM13 monotherapy in adult patients with recurrent/refractory CD30-positive lymphomas.

* All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%.

* There were no observed events of cytokine release syndrome, neurotoxicity syndrome, or graft-versus-host disease.

* The study is continuing enrollment of the second dose cohort.

* The company will host a conference call/webcast on April 14 at 4:05 p.m. E.T.

* Price Action: AFMD shares rise 40.8% at $11.05 in the premarket session on the last check Friday.